Drug Profile
Research programme: ACE2 stimulants - Nippon Chemiphar
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nippon Chemiphar
- Class
- Mechanism of Action ACE stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Pulmonary-arterial-hypertension in Japan
- 31 Mar 2013 Early research in Pulmonary arterial hypertension in Japan